-
1.
公开(公告)号:US20150299728A1
公开(公告)日:2015-10-22
申请号:US14792247
申请日:2015-07-06
申请人: AlphaVax, Inc.
CPC分类号: C12N15/86 , A61K39/0011 , A61K39/12 , A61K39/21 , A61K48/00 , A61K2039/5256 , A61K2039/5258 , A61K2039/575 , C07K14/005 , C12N7/00 , C12N2740/16222 , C12N2740/16234 , C12N2770/36123 , C12N2770/36134 , C12N2770/36143 , C12N2770/36152 , C12N2770/36162 , C12N2840/203
摘要: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.
摘要翻译: 本公开提供了TC-83VEE衍生的复制子,甲病毒复制子颗粒和含有TC-83甲病毒复制子颗粒的免疫原性组合物,其在引入合适的宿主细胞时引导至少一种抗原的表达。 本文描述的TC-83VEE衍生的ARP被改进,因为它们比现有技术的ARP受到较低的载体特异性免疫应答。
-
公开(公告)号:US10570416B2
公开(公告)日:2020-02-25
申请号:US15234949
申请日:2016-08-11
申请人: ALPHAVAX, INC.
摘要: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.
-
公开(公告)号:US09441247B2
公开(公告)日:2016-09-13
申请号:US14792247
申请日:2015-07-06
申请人: AlphaVax, Inc.
CPC分类号: C12N15/86 , A61K39/0011 , A61K39/12 , A61K39/21 , A61K48/00 , A61K2039/5256 , A61K2039/5258 , A61K2039/575 , C07K14/005 , C12N7/00 , C12N2740/16222 , C12N2740/16234 , C12N2770/36123 , C12N2770/36134 , C12N2770/36143 , C12N2770/36152 , C12N2770/36162 , C12N2840/203
摘要: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.
-
公开(公告)号:US09079943B2
公开(公告)日:2015-07-14
申请号:US14229736
申请日:2014-03-28
申请人: AlphaVax, Inc.
IPC分类号: C12N15/86 , C07K14/005 , A61K39/21 , C12N7/00 , A61K39/193 , A61K39/295 , A61K48/00 , A61K39/00
CPC分类号: C12N15/86 , A61K39/0011 , A61K39/12 , A61K39/21 , A61K48/00 , A61K2039/5256 , A61K2039/5258 , A61K2039/575 , C07K14/005 , C12N7/00 , C12N2740/16222 , C12N2740/16234 , C12N2770/36123 , C12N2770/36134 , C12N2770/36143 , C12N2770/36152 , C12N2770/36162 , C12N2840/203
摘要: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.
摘要翻译: 本公开提供了TC-83VEE衍生的复制子,甲病毒复制子颗粒和含有TC-83甲病毒复制子颗粒的免疫原性组合物,其在引入合适的宿主细胞时引导至少一种抗原的表达。 本文描述的TC-83VEE衍生的ARP被改进,因为它们比现有技术的ARP受到较低的载体特异性免疫应答。
-
-
-